Oncotide Pharmaceuticals Inc. believes it has found a way to deactivate the phosphorylation that is a driver of oncogenic signaling, an approach that could provide an alternative or add-on to kinase inhibitors for blocking growth of tumor cells.

Rather than inhibiting kinases to restore normal phosphorylation and reduce the signaling of up-regulated oncogenic pathways, Oncotide is developing SET inhibitors to promote dephosphorylation of the oncogenic signaling molecules.